Terms: = Pancreatic cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
10144 results:
1. Current Roles of Ramucirumab in the Sequential treatment of Unresectable Hepatocellular Carcinoma.
Koizumi A; Komatsu S; Omiya S; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; So S; Yoshida T; Arai K; Fujinaka R; Shimura Y; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2024 May; 44(5):2055-2061. PubMed ID: 38677746
[TBL] [Abstract] [Full Text] [Related]
2. Multimodal Approaches to Patient Selection for Pancreas cancer Surgery.
Muaddi H; Kearse L; Warner S
Curr Oncol; 2024 Apr; 31(4):2260-2273. PubMed ID: 38668070
[TBL] [Abstract] [Full Text] [Related]
3. [A Case of Advanced Gastric cancer Treated with Conversion Surgery followed by Nivolumab Combination Chemotherapy].
Sekino N; Natsume T; Tanaka H; Kainuma O; Sato Y; Note H; Yoshioka T; Kamata T; Odera H; Uchiyama M; Maruyama T; Takahashi H; Hirano S
Gan To Kagaku Ryoho; 2024 Apr; 51(4):417-420. PubMed ID: 38644309
[TBL] [Abstract] [Full Text] [Related]
4. [The efficacy and safety of laparoscopic radical gastrectomy after neoadjuvant chemotherapy combined with immunotherapy and targeted therapy].
Shao XX; Li WK; Hu HT; Lu YM; Jiang YJ; Tian YT
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1397-1402. PubMed ID: 38644290
[No Abstract] [Full Text] [Related]
5. [cancer survival analysis in Tianjin, 2010 to 2016].
Wang C; Shen CF; Xun LN; Zhang S; Zhang H; Zheng WL; Wang DZ
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):319-325. PubMed ID: 38644267
[No Abstract] [Full Text] [Related]
6. Prognostic value of combined psoas muscle mass and controlling nutritional status in patients with pancreatic ductal adenocarcinoma: a retrospective cohort study.
Kuwabara S; Takeuchi Y; Sato O; Mizota T; Ichinokawa M; Murakawa K; Aoki Y; Ishido K; Ono K; Hirano S
BMC Surg; 2024 Apr; 24(1):116. PubMed ID: 38643112
[TBL] [Abstract] [Full Text] [Related]
7. Defining distal splenopancreatectomy by the mesopancreas.
Safi SA; Alexander A; Neuhuber W; Haeberle L; Rehders A; Luedde T; Esposito I; Fluegen G; Knoefel WT
Langenbecks Arch Surg; 2024 Apr; 409(1):127. PubMed ID: 38625602
[TBL] [Abstract] [Full Text] [Related]
8. CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival.
Wedig J; Jasani S; Mukherjee D; Lathrop H; Matreja P; Pfau T; D'Alesio L; Guenther A; Fenn L; Kaiser M; Torok MA; McGue J; Sizemore GM; Noonan AM; Dillhoff ME; Blaser BW; Frankel TL; Culp S; Hart PA; Cruz-Monserrate Z; Mace TA
Cancer Immunol Immunother; 2024 Apr; 73(6):96. PubMed ID: 38619621
[TBL] [Abstract] [Full Text] [Related]
9. treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer.
Zhang LT; Zhang Y; Cao BY; Wu CC; Wang J
World J Gastroenterol; 2024 Mar; 30(12):1739-1750. PubMed ID: 38617739
[TBL] [Abstract] [Full Text] [Related]
10. Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in pancreatic Ductal Carcinoma.
Fujiwara-Tani R; Sasaki T; Bhawal UK; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Fujii K; Ohmori H; Sho M; Kuniyasu H
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612866
[TBL] [Abstract] [Full Text] [Related]
11. Feasibility, safety and oncological short-term outcome of laparoscopic pancreaticoduodenectomy for periampullary cancer: Findings from a large sample from Vietnam.
Pham HM; Le Quan AT; Nguyen BH
Medicine (Baltimore); 2024 Apr; 103(15):e37769. PubMed ID: 38608081
[TBL] [Abstract] [Full Text] [Related]
12. Genetic Signature of Human pancreatic cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract] [Full Text] [Related]
13. Predicting postoperative prognosis of pancreatic cancer using a computed tomography-based radio-clinical model: exploring biologic functions.
Yu C; Ruan Y; Yu L; Wang X; Hu Z; Zhu G; Huang T
J Gastrointest Surg; 2024 Apr; 28(4):458-466. PubMed ID: 38583896
[TBL] [Abstract] [Full Text] [Related]
14. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
[TBL] [Abstract] [Full Text] [Related]
15. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
16. A Network Meta-analysis of the Efficacy of Drug Therapy in First-line treatment of Advanced Hepatocellular Carcinoma.
Wang X; Peng G; Li J
J Gastrointestin Liver Dis; 2024 Mar; 33(1):94-101. PubMed ID: 38554414
[TBL] [Abstract] [Full Text] [Related]
17. Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomes.
Prajapati R; Ostwal V; Srinivas S; Engineer R; Bhargava P; Saklani A; D'Souza A; Kumar S; Peelay Z; Manali P; Ramaswamy A
J Cancer Res Ther; 2024 Jan; 20(1):199-203. PubMed ID: 38554321
[TBL] [Abstract] [Full Text] [Related]
18. A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.
Shi JM; Li N; Jiang LM; Yang L; Wang SL; Song YW; Liu YP; Fang H; Lu NN; Qi SN; Chen B; Li YX; Zhao DB; Tang Y; Jin J
Sci Rep; 2024 Mar; 14(1):7522. PubMed ID: 38553594
[TBL] [Abstract] [Full Text] [Related]
19. A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancer.
Xuan M; Li N; Wu C
Clinics (Sao Paulo); 2024; 79():100348. PubMed ID: 38552386
[TBL] [Abstract] [Full Text] [Related]
20. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
Musher BL; Rowinsky EK; Smaglo BG; Abidi W; Othman M; Patel K; Jawaid S; Jing J; Brisco A; Leen AM; Wu M; Sandin LC; Wenthe J; Eriksson E; Ullenhag GJ; Grilley B; Leja-Jarblad J; Hilsenbeck SG; Brenner MK; Loskog ASI
Lancet Oncol; 2024 Apr; 25(4):488-500. PubMed ID: 38547893
[TBL] [Abstract] [Full Text] [Related]
[Next]
